Saisuwan Krittamate, Boonnate Piyanard, Goto Hiroki, Nakagawa Rumi, Abe Makoto, Hirabayashi Kaoru, Fujiwara Yukio, Kikuta Kazutaka, Okada Seiji
Division of Hematopoiesis, Joint Research Center for Human Retrovirus Infection & Graduate, School of Medical Sciences, Kumamoto University, 2-2-1 Honjo, Chuo-ku, Kumamoto, 860-0811, Japan.
Laboratory of Environmental and Toxicology, Chulabhorn Research Institute, Kamphaeng Phet 6 Rd, Talat Bang Khen, Lak Si, Bangkok, 10210, Thailand.
Hum Cell. 2025 Jun 3;38(4):116. doi: 10.1007/s13577-025-01235-6.
Dedifferentiated chondrosarcoma (DDCS) is a rare and aggressive subtype of chondrosarcoma, characterized by the coexistence of a high-grade spindle or pleomorphic tumor that lacks a substantial cartilaginous matrix. Notably, it shows a mutant IDH1 incidence of over 80%. This study established a novel DDCS cell line with an IDH1 mutation, TK-DDCS1, derived from the right ilium of a 67-year-old Japanese female patient. TK-DDCS1 cells maintain the undifferentiated DDCS phenotype with the IDH1p.R132L mutation. The IDH1R132 mutation is known to be associated with a poor prognosis for chondrosarcoma, and the p.R132L mutation is a novel variant among the registered DDCS cell lines in the Cellosaurus database. The mutant IDH1 inhibitor, DS-1001b, inhibited the proliferation of TK-DDCS1 in a dose-dependent manner in both two-dimensional and spheroid cultures. The tumorigenicity of TK-DDCS1 was demonstrated through xenografting into EGFP-transgenic BALB/c Rag2-/-/Jak3-/- (EGFP-BRJ) mice, where the tumors exhibited undifferentiated phenotypes of DDCS in both morphological and immunohistochemical features. Thus, TK-DDCS1 serves as a valuable model for investigating the characteristics of DDCS and exploring molecular targeted therapies.
去分化软骨肉瘤(DDCS)是软骨肉瘤中一种罕见且侵袭性强的亚型,其特征是存在高级别的梭形或多形性肿瘤,且缺乏大量软骨基质。值得注意的是,其异柠檬酸脱氢酶1(IDH1)突变发生率超过80%。本研究建立了一种具有IDH1突变的新型DDCS细胞系TK-DDCS1,该细胞系源自一名67岁日本女性患者的右髂骨。TK-DDCS1细胞维持着具有IDH1p.R132L突变的未分化DDCS表型。已知IDH1R132突变与软骨肉瘤的不良预后相关,且p.R132L突变是细胞osaurus数据库中已注册的DDCS细胞系中的一种新型变体。突变型IDH1抑制剂DS-1001b在二维和球体培养中均以剂量依赖方式抑制TK-DDCS1的增殖。通过将TK-DDCS1异种移植到增强型绿色荧光蛋白(EGFP)转基因BALB/c Rag2-/-/Jak3-/-(EGFP-BRJ)小鼠中,证实了TK-DDCS1的致瘤性,所形成的肿瘤在形态和免疫组化特征上均表现出DDCS的未分化表型。因此,TK-DDCS1是研究DDCS特征和探索分子靶向治疗的有价值模型。